Escient Pharmaceuticals commences trial-based study of EP262, an innovative, orally-taken MRGPRX2 blocker for chronic inducible hives.

This article summarized the latest R&D progress of Prednisolone Sodium Phosphate, the Mechanism of Action for Prednisolone Sodium Phosphate, and the drug target R&D trends for Prednisolone Sodium Phosphate.

The full name is the Ethics Committee, an independent organization composed of medical professionals, legal experts, and non-medical personnel.

This article summarized the latest R&D progress of Risdiplam, the Mechanism of Action for Risdiplam, and the drug target R&D trends for Risdiplam.

Data provided by Longhorn vaccine and diagnostics indicate that lhnvd-201 has neutralizing activity against covid-19 and influenza coinfection.

This article summarized the latest R&D progress of Sodium Salicylate, the Mechanism of Action for Sodium Salicylate, and the drug target R&D trends for Sodium Salicylate.

Proteasomes are a key component of the ubiquitin-proteasome pathway, a central platform for recycling proteins involved in crucial cellular processes, including cell cycle progression, DNA repair, and transcription.

This article summarized the latest R&D progress of Tolbutamide, the Mechanism of Action for Tolbutamide, and the drug target R&D trends for Tolbutamide.

Appili Therapeutics a biodefense and infectious disease drug company, announced that its production and marketing partner, Saptalis Pharmaceuticals, received US FDA approval for Metronidazole Oral Suspension 500mg/5mL.

This article summarized the latest R&D progress of Trofinetide, the Mechanism of Action for Trofinetide, and the drug target R&D trends for Trofinetide.

Programmed cell death protein-1 (PD-1) is an important immune inhibitory molecule, belonging to the immunoglobulin superfamily.

This article summarized the latest R&D progress of Dexmethylphenidate Hydrochloride, the Mechanism of Action for Dexmethylphenidate Hydrochloride, and the drug target R&D trends for Dexmethylphenidate Hydrochloride.